EDE. E. Dubinina

E. E. Dubinina

*This is an algorithmically generated author record based on publicly available information.

E. E. Dubinina has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Correlation network of metabolic indicators in cognitive impairment and normal aging in the elderly

    by N.M. Zalutskaya, E.E. Dubinina, N.A. Gomzyakova, K.V. Yushchin, L.V. Shchedrina, R.R. Fajzrahmanov, N.G. Neznanov

    Objective. To conduct a comparative assessment of metabolic, hematological, and antioxidant parameters in the peripheral blood of cognitively intact elderly individuals versus patients experiencing mild cognitive impairment, as well as to establish the correlations among the studied metrics within the respective groups. Material and methods. The cross-sectional cohort study included 172 outpatients aged 60 years and older, who were assessed at the V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology. Two groups were established: one comprising patients with mild cognitive impairment (n=118) and another with cognitively intact individuals (n=54). Participants underwent clinical and neuropsychological assessments, as well as magnetic resonance imaging of the brain. A laboratory examination of fasting venous blood was performed, encompassing evaluations of hematological and biochemical parameters, antioxidant enzyme activities, and the profile of polyunsaturated fatty acids using gas chromatography. Non-parametric comparison methods and correlation analyses were applied (p≤0.05). Results. The findings indicated that patients with mild cognitive impairment exhibited a statistically significant reduction in the activities of superoxide dismutase (1412 IU/g of Hb and 1512.98 IU/g of Hb, respectively; p=0.048), catalase (7.17 IU/mL and 9.03 IU/mL; p<0.001), and glutathione peroxidase (47.81 IU/mL and 69.22 IU/mL of erythrocyte suspension; p<0.001). Additionally, the concentrations of eicosapentaenoic acid (3.10 μg/mL and 4.20 μg/mL; p=0.004) and docosahexaenoic acid (8.85 μg/mL and 11.80 μg/mL; p=0.005) were notably decreased. Correlation analysis revealed an increase in intersystemic relationships among lipid metabolism, the antioxidant system, and hematological parameters, alongside a decrease in intrasystem correlations compared with the cognitively intact group. Conclusions. The study results suggest that mild cognitive impairment is associated with initial signs of metabolic dysregulation and a reorganization of metabolic system integration. These findings may be significant for stratifying risk associated with cognitive impairment.

  • Oxidative stress and depression in Parkinson’s disease

    by S.A. Trofimova, L.V. Lukina, V.A. Mikhailov, E.E. Dubinina

    Objective. The aim of this study was to study the complex relationship between markers of oxidative stress and depression in patients diagnosed with Parkinson’s disease, with an emphasis on how various therapeutic interventions affect these biochemical parameters. Material and methods. The study included 60 participants (26 women and 34 men, average age 65.13±0.84 years) who received Fluvoxamine 100 mg/day as monotherapy (main group, n=30) or combination therapy (comparison group, n=30), including the antioxidant Cytoflavin and Fluvoxamine 100 mg/day. The control group consisted of 20 practically healthy elderly people. Using clinical, psychometric, and statistical research methods, the dynamics of depression symptoms and markers of oxidative stress in patients diagnosed with Parkinson’s disease were evaluated during a three-month course of treatment with Fluvoxamine and Cytoflavin. Results. During 3 months of therapy, the average score on the Hamilton depression scale in the main group decreased from 26.63±0.33 to7.22±0.5 points (p<0.01), in the comparison group from 26.51±0.29 to 12.18±1.1 points. According to the HADS scale, the average score in the main group decreased from 15.46±0.8 to 7.1±0.1 points (p<0.05), and in the comparison group from 15.14±0.8 to 9.7±1.2 points. After the therapy, all patients showed a significant slowdown in lipid peroxidation processes, an increase in the concentration of antioxidant enzymes, and a statistically significant (p<0.01) increase in the concentration of reduced glutathione, with a more significant improvement in the main group. Conclusion. The results of a comparative analysis of the effectiveness of treatment of depression in patients with Parkinson’s disease showed that the use of a combination of Fluvoxamine and Cytoflavin provides a more pronounced therapeutic effect compared with Fluvoxamine monotherapy. These findings emphasize the need to integrate combined approaches into the development of new treatment strategies for depressive states based on a personalized assessment of the clinical picture of depressive disorder and biomarkers of oxidative stress.

  • Open Access

    Homocysteine in Schizophrenia: Independent Pathogenetic Factor with Prooxidant Activity or Integral Marker of Other Biochemical Disturbances?

    by T. V. Zhilyaeva, A. S. Piatoikina, A. P. Bavrina, O. V. Kostina, E. S. Zhukova, T. G. Shcherbatyuk, A. S. Blagonravova, E. E. Dubinina, G. E. Mazo

    A wide range of studies have demonstrated that hyperhomocysteinemia is associated with the risk of schizophrenia, but currently available assumptions about the direct involvement of homocysteine (Hcy) in the pathogenesis of schizophrenia are hypothetical. It is possible that in vivo Hcy is only a marker of folate metabolism disturbances (which are involved in methylation processes) and is not a pathogenetic factor per se. Only one study has been conducted in which associations of hyperhomocysteinemia with oxidative stress in schizophrenia (oxidative damage to protein and lipids) have been found, and it has been suggested that the oxidative stress may be induced by the elevated Hcy in schizophrenic patients. But the authors did not study the level of reduced glutathione (GSH), as well as possible causes of hyperhomocysteinemia—disturbances of folate metabolism. The aim of this work is to analyze the association of Hcy levels with the following: (1) redox markers in schizophrenia GSH, markers of oxidative damage of proteins and lipids, and the activity of antioxidant enzymes in blood serum; (2) with the level of folate and cobalamin (В12); and (3) with clinical features of schizophrenia measured using the Positive and Negative Syndrome Scale (PANSS). 50 patients with schizophrenia and 36 healthy volunteers, matched by sex and age, were examined. Hcy in patients is higher than in healthy subjects (p = 0.0041), and this may be due to the lower folate level in patients (p = 0.0072). In patients, negative correlation was found between the level of Hcy both with the level of folate (ρ = −0.38, p = 0.0063) and with the level of B12 (ρ = −0.36, p = 0.0082). At the same time, patients showed higher levels of oxidative modification of serum proteins (p = 0.00046) and lower catalase (CAT) activity (p = 0.014). However, Hcy is not associated with the studied markers of oxidative stress in patients. In the group of patients with an increased level of Hcy (>10 μmol/l, n = 42) compared with other patients (n = 8), some negative symptoms (PANSS) were statistically significantly more pronounced: difficulty in abstract thinking (N5, p = 0.019), lack of spontaneity and flow in conversation (N6, p = 0.022), stereotyped thinking (N7, p = 0.013), and motor retardation (G7, p = 0.050). Thus, in patients with schizophrenia, hyperhomocysteinemia caused by deficiency of folate and B12 is confirmed and can be considered a marker of disturbances of vitamin metabolism. The redox imbalance is probably not directly related to hyperhomocysteinemia and is hypothetically caused by other pathological processes or by an indirect effect of Hcy, for example, on the enzymatic antioxidant defence system (CAT activity), which requires further exploration. Further study of the role of Hcy in the pathogenesis of schizophrenia is relevant, since the proportion of patients with hyperhomocysteinemia is high and correlations of its level with negative symptoms of schizophrenia are noted.